HARPOON THERAPEUTICS INC (HARP) Stock News
NASDAQ:HARP - Nasdaq - US41358P2056 - Common Stock - Currency: USD
HARP Latest News, Press Relases and Analysis
Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth
Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, and EPS outlook for 2024.
Mentions: MRK
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Cellectar Biosciences stock is up on Monday as investors celebrate positive study results with heavy trading of CLRB stock this morning.
Mentions: CLRB
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.
The 3 Best Dividend Growth Stocks to Buy in January 2024
These are the best dividend growth stocks to buy as they represent companies with healthy free cash flow upside visibility.
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
Harpoon Therapeutics stock is rocketing higher on Monday as HARP investors react to Merck acquiring the company for $23 per share.
Mentions: MRK
FDA approves Merck's Keytruda for FIGO 2014 cervical cancer (NYSE:MRK)
Merck (MRK) said the FDA has approved Keytruda in combination with chemoradiotherapy for the treatment of FIGO 2014 Stage III-IVA cervical cancer. Read more here.
Mentions: MRK
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Barron’s cites cancer and weight loss plays for biotech M&A (NASDAQ:VKTX)
On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.
Harpoon Therapeutics could see interest from other parties, Oppenheimer says
Harpoon Therapeutics could attract other bidders after agreeing to a $23 per share sale to Merck, according to an Oppenheimer analyst.
Mentions: MRK
J&J, Merck and Boston Scientific Go on $6.4 Billion Buying Spree
More than $6.4 billion in health-care deals were announced on Monday at the annual JPMorgan Healthcare Conference in San Francisco as companies like Johnson & Johnson and Merck & Co. look to acquisitions to replenish their revenue streams.
Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck
/PRNewswire/ -- Ademi LLP is investigating Harpoon (Nasdaq: HARP) for possible breaches of fiduciary duty and other violations of law in its transaction with...
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news.
Why Is Spirit AeroSystems (SPR) Stock Down 14% Today?
Spirit AeroSystems stock is falling hard on Monday as investors in SPR react to one of the company's flights experiencing a mid-air blowout.
Why Is LumiraDx (LMDX) Stock Down 13% Today?
LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!